

Yahsou Delmas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5178782/publications.pdf>

Version: 2024-02-01

16
papers

1,353
citations

687363

13
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

1255
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney International</i> , 2015, 87, 1061-1073.	5.2	342
2	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 50-59.	4.5	148
3	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1237-1247.	4.5	146
4	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. <i>Kidney International</i> , 2020, 97, 1287-1296.	5.2	123
5	A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. <i>Blood</i> , 2021, 137, 733-742.	1.4	95
6	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. <i>Blood</i> , 2021, 137, 2438-2449.	1.4	87
7	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , 2020, 136, 2103-2117.	1.4	82
8	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2449-2463.	6.1	81
9	Atypical and secondary hemolytic uremic syndromes have a distinct presentation and a common genetic risk factors. <i>Kidney International</i> , 2019, 95, 1443-1452.	5.2	74
10	Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2122-2130.	0.7	72
11	Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. <i>Blood</i> , 2019, 134, 2209-2217.	1.4	38
12	Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 243-244.	2.9	30
13	Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: A pediatric report and literature review. <i>Pediatric Critical Care Medicine</i> , 2011, 12, e90-e93.	0.5	16
14	Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2147-2153.	0.7	15
15	Urine Protein/Creatinine Ratio in Thrombotic Microangiopathies: A Simple Test to Facilitate Thrombotic Thrombocytopenic Purpura and Hemolytic and Uremic Syndrome Diagnosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 648.	2.4	3
16	Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes. <i>Journal of Clinical Medicine</i> , 2022, 11, 790.	2.4	1